Original paper
Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib
Abstract
•Selpercatinib and pralsetinib both have high extracranial efficacy in RET fusion-positive non-small cell lung cancer (NSCLC). •We present a case of a patient with RET fusion-positive NSCLC who had a durable extracranial response to pralsetinib, but had leptomeningeal progression. She subsequently had both a clinical and radiographic CNS response to selpercatinib. •Future studies should compare the intracranial efficacy with these 2 RET...
Paper Details
Title
Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib
Published Date
Jan 1, 2022
Journal
Volume
23
Issue
1
Pages
e5 - e8
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History